Bionxt closes first tranche of debenture unit financing

Mr. Hugh Rogers reports BIONXT SOLUTIONS ANNOUNCES CLOSING OF FIRST TRANCHE OF CONVERTIBLE DEBENTURE UNIT PRIVATE PLACEMENT Bionxt Solutions Inc. has closed the first tranche of its previously announced non-brokered private placement of convertible debenture units at a price of 60 cents per debenture unit, for gross proceeds of $1,009,200. The $1,009,200 represents the principal amount outstanding pursuant to the debentures (as defined herein); the company also issued 1,682,000 warrants (as defined herein) pursuant to the closing of the first tranche of the offering. Each debenture unit consisted of: (i) 60 cents of principal amount of 8.0 per cent unsecured convertible debentures; and (ii) one common share purchase warrant. Each warrant entitles the holder to acquire one common share in the capital of the company at a price of 75 cents per common share for a period of two years following the date of issuance. The debentures bear interest from their issue date at 8.0 per cent per annum on an accrual basis, calculated and payable on an annual basis, up to and including the date that is two years following the date of issuance. The principal amount of the debentures is convertible, at the option of the holder, into common shares at any time prior to the maturity date, at a conversion price of 60 cents per common share. At the election of the company, the interest payable on the principal amount of the debentures may be settled by a cash payment or through the issuance of common shares at the conversion price. The company intends to use the net proceeds from the offering for product development and commercialization, intellectual property filings, and general working capital. In connection with the closing of the first tranche of the offering, the company paid an aggregate cash finder's fee of $80,736 and issued an aggregate of 134,560 finder's warrants to Canaccord Genuity Corp. Each finder's warrant will entitle the holder to purchase one common share at an exercise price of 60 cents per finder's share for a period of two years from the date of issuance of the finder's warrants. The securities of the company issued in connection with the first tranche of the offering, and any common shares issuable upon conversion or exercise thereof, are subject to a statutory hold period until Nov. 26, 2025, in accordance with applicable Canadian securities laws. About Bionxt Solutions Inc. Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms, sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets), target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide. Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF, and in Germany under WKN: A3D1K3. We seek Safe Harbor.